A new collaboration will use generative AI for the early discovery stage of novel Central Nervous System (CNS) disease therapies, developing small molecule inhibitors from scratch.
The collaboration is between biotech company Insilico Medicine and biopharma company Tenacia Biotechnology.
The collaboration will combine Insilico’s Pharma.AI – a generative AI-based drug discovery platform – and its research and development expertise with Tenacia’s specialised scientific and clinical knowledge.
The joint effort will focus on creating transformative treatments for Central Nervous System (CNS) disorders, with a particular emphasis on developing blood-brain barrier (BBB) penetrable small molecule inhibitors.
By leveraging advanced AI technologies, the partnership seeks to expand therapeutic options and enhance outcomes for patients worldwide.
“With multiple pipelines already in the clinical stage, we hope to further expand our CNS-focused therapeutics portfolio and look forward to benefitting from our collaboration with Insilico Medicine,” said Xiaoxiang Chen, founder and CEO of Tenacia.
“By combining Insilico’s revolutionary AI-driven platform with Tenacia’s deep expertise in CNS biology and clinical development, we anticipate being able to contribute even more to the shift of treatment paradigm.”
“This collaboration represents the next step in demonstrating the transformative power of AI in drug discovery,” said Alex Zhavoronkov, founder and CEO of Insilico Medicine.
“By partnering with Tenacia, we are showcasing how targeted expertise, driven by generative AI, can unlock new solutions for CNS diseases, especially in overcoming the challenge of crossing the blood-brain barrier.”
Recently, Insilico announced the nomination of ISM8969, a BBB penetrable NLRP3 inhibitor against inflammation-related diseases including Alzheimer’s disease and epilepsy, further enhancing Insilico’s portfolio against CNS disorders and aging-related diseases.
